Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
One of the foremost challenges is the incomplete elucidation of -CC signaling mechanisms
Endocrinol Connect
FUGENE HD transfection reagent for generation of P0 virus and Wizard Plus SV Minipreps DNA Purification System were purchased from Promega
When administered therapeutically, GLP-1 receptor agonists work through several mechanisms: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner [1] [4] Suppressing glucagon release from alpha cells, reducing hepatic glucose output Slowing gastric emptying , which helps moderate post-meal blood glucose rises Promoting satiety through central nervous system pathways, potentially supporting weight reduction Investigational transdermal GLP-1 delivery systems typically utilise specialised technologies such as microneedles or active delivery methods rather than conventional patches, as GLP-1 molecules are large peptides that do not easily penetrate the skin barrier
10.1016/j.plaphy.2015.11.005 Plant Physiol
